NSCLC Coverage From Every Angle

Recent News

Interstitial Pneumonitis and Nivolumab Combination Therapy for Lung Cancer
FDA Expands Approval of Durvalumab in Advanced Unresectable Lung Cancer
FDA Grants Priority Review to Lorlatinib in ALK-Positive Lung Cancer
Benefits of Newer Risk-Based Criteria for Lung Cancer Screening
Benefit of Sequential Chemotherapy Followed by Postoperative Radiotherapy for Patients With Lung Cancer
Updated Guidelines for Molecular Testing and Targeted Therapies in Lung Cancer
ASCO-SITC 2018: Study Sheds Light on Immune Microenvironment of Lung Tumors
Smoking History and Molecular Testing for Lung Adenocarcinoma
Path and Evolution of Drug-Resistant Clones in Lung Cancer
Novel Approach to Targeted Therapy in NSCLC
First-in-Human Biologic Drug Combination for Metastatic Lung Cancer
FDA Expands Afatinib Indication in First-Line Treatment of Metastatic Lung Cancer
Adjuvant Treatments Compared for EGFR-Mutant Lung Cancer
Aggressive Surgery for Patients With Early-Stage Lung Cancer
Potential of Beta-Blockers in Preventing Resistance to EGFR Inhibitors in Lung Cancer
Timing of Lobectomy and Survival in Squamous Cell Lung Cancer
Ado-trastuzumab Emtansine Therapy for HER2-Mutant or Amplified Lung Cancers
Entrectinib for Locally Advanced or Metastatic ROS1 Fusion–Positive NSCLC
FDA Accepts New Drug Application for First-Line Osimertinib in EGFR-Mutated NSCLC
Nab-Paclitaxel Plus Durvalumab as Second/Third-Line Treatment of Advanced NSCLC
European Union Position Statement on Lung Cancer Screening
IASLC Releases Atlas of EGFR Testing in Lung Cancer
ALUR Trial: Alectinib and CNS Metastases in ALK-Positive NSCLC
Early Results With Poziotinib in EGFR-Mutant Lung Cancer
SLND and Contralateral Mediastinal Lymphadenectomy for Non–Small Cell Lung Cancer
ESMO Asia 2017: Osimertinib in Asian Patients With EGFR-Mutated Lung Cancer
ESMO Asia 2017: Mutations in Blood and CSF of Lung Cancer Patients With Brain Metastases
ESMO Asia 2017: Alectinib vs. Crizotinib in Asian Patients With Lung Cancer
Combination Therapy With Demcizumab in Nonsquamous Lung Cancer
Brigatinib in Crizotinib-Refractory NSCLC
AORTIC 2017: Lung Cancer Incidence Rates and Smoking Trends In South Africa
AACR-NCI-EORTC 2017: Combination Therapy With New Antibody-Drug Conjugate in Mesothelioma or Lung Cancer
FDA Approves Alectinib as First-Line Treatment of ALK-Positive Metastatic Lung Cancer
Clinical Efficacy of Atezolizumab in PD-L1 NSCLC Subgroups
Dacomitinib Versus Gefitinib in First-Line Setting for Advanced NSCLC Subgroup
CHEST 2017: American College of Chest Physicians Releases Updated Lung Cancer Screening Guideline
Concurrent EGFR Tyrosine Kinase Inhibitor Therapy With Radiation Therapy in NSCLC
WCLC 2017: Pemetrexed/Carboplatin Plus Pembrolizumab in Nonsquamous NSCLC
WCLC 2017: Pembrolizumab Plus CC-486 for NSCLC
Palliative Care Symposium 2017: Yoga Therapy for Lung Cancer Patients
WCLC 2017: Updated Results of Nivolumab and Chemotherapy in Advanced Non–Small Cell Lung Cancer
FDA Accepts Supplemental Biologics License Application for Durvalumab in Unresectable NSCLC
WCLC 2017: Lorlatinib in ALK-Positive/ROS1-Positive Advanced Lung Cancer
WCLC 2017: Quality of Life of Patients With NSCLC Treated With Durvalumab
WCLC 2017: Plasma ctDNA Analysis In EGFRm-Positive Patients With Advanced NSCLC
WCLC 2017: 3-Year Survival With Atezolizumab Versus Docetaxel in Non–Small Cell Lung Cancer
WCLC 2017: Ramucirumab Plus Docetaxel in Second-Line Treatment of Advanced NSCLC
WCLC 2017: Ramucirumab Plus Docetaxel in Second-Line Treatment of Advanced NSCLC
Breakthrough Therapy Designation Granted for Osimertinib as First-Line Treatment for EGFR-Positive Non–Small Cell Lung Cancer
ASTRO 2017: Trimodality Therapy Versus Concurrent Chemoradiation in Advanced NSCLC
ASTRO 2017: Chemotherapy Plus EGFR Tyrosine Kinase Inhibitors in NSCLC
ASTRO 2017: Gene Aberrations in Patients With Lung Adenocarcinomas Undergoing SBRT
ASTRO 2017: Tumor-Specific Modeling to Stratify Lung Cancer Patients for Therapy
ASTRO 2017: Predicting Response to Lung Cancer Treatment With Circulating Tumor DNA Analysis
ASTRO 2017: Long-Term Survival With Standard-Dose Chemoradiation in Stage III Lung Cancer
ESMO 2017: First-line Crizotinib Versus Chemotherapy in ALK-Positive Lung Cancer
ESMO 2017: Addition of Pembrolizumab to Chemotherapy for Advanced Nonsquamous Lung Cancer
ESMO 2017: Continuous vs. Fixed-Duration Nivolumab in Patients With Advanced NSCLC
ESMO 2017: Nivolumab vs Docetaxel in Advanced Non–Small Cell Lung Cancer
First Biosimilar for the Treatment of Cancer Approved by FDA
ESMO 2017: Are Follow-up CT Scans Necessary After Surgery for Non–Small Cell Lung Cancer?
ESMO 2017: PD-L1 Inhibitor Durvalumab for Stage III Locally Advanced Lung Cancer
ESMO 2017: Osimertinib as First-Line Therapy for EGFR Mutation–Positive Lung Cancer
KEYNOTE-001: Radiotherapy Combined With Pembrolizumab in Advanced Lung Cancer
Updated ASCO Guideline on Stage IV Non–Small Cell Lung Cancer Therapy
Lung Cancer Clinical Trial Eligibility and Requirements
Retreatment With Immunotherapy After Toxicity in Lung Cancer Patients
Targeted Therapy for Patients With HER2-Positive Advanced Lung Cancer
Investigational First-Line Combination Treatment for EGFR-Mutant Lung Cancers
Ado-trastuzumab Emtansine in HER2-Overexpressing Metastatic NSCLC
Priority Review Granted for Alectinib for Initial Treatment of ALK-Positive Lung Cancer
Durvalumab Granted Breakthrough Therapy Designation in Locally Advanced Lung Cancer
ASCO 2017: Impact of MET Inhibitors on Survival in Non–Small Cell Lung Cancer
ASCO 2017: First-in-Class Cancer Stemness Inhibitor in Nonsquamous NSCLC
ASCEND-5: Ceritinib vs Chemotherapy in Advanced ALK-Rearranged NSCLC
Companion Diagnostic Test to Screen Multiple Lung Cancer Therapies Receives FDA Approval
Targeting Trop-2 in Advanced Non–Small Cell Lung Cancer
First-Line Treatment of Nivolumab in Advanced Lung Cancer
Five-Year Survival With Nivolumab in Advanced Lung Cancer
Jumonji C Inhibitors and Chemotherapy-Resistant Lung Cancer
Combination Therapy for Metastatic NSCLC With BRAF V600E Mutation Granted FDA Approval
ASTRO Issues New Guideline on SBRT in Early-Stage Lung Cancer
Lung Cancer Diagnosis and Risk of Suicide
ASCO 2017: KEYNOTE-024 Update on Pembrolizumab in Advanced Lung Cancer
ASCO 2017: Update on New Second-Generation EGFR Inhibitor
ASCO 2017: Alectinib vs Crizotinib in ALK-Positive Lung Cancer
ASCO 2017: Bevacizumab Beyond Disease Progression in Advanced Lung Cancer
ELCC 2017: EGFR Mutation and Circulating Tumor DNA
Expanded Indication for Ceritinib to Previously Untreated ALK-Positive Lung Cancer
ELCC 2017: Ensartinib in ALK-Positive Lung Cancer
IASLC Releases Immunotherapy Atlas
ELCC 2017: Blood Biomarkers May Shed Light on Patients Most Likely to Benefit From Immunotherapy
ELCC 2017: Osimertinib and Symptom Control in Advanced Lung Cancer
ASCO 2017 Preview: Adjuvant Gefitinib in EGFR-Mutated Lung Cancer
Potential Predictive Biomarker of Response to Crizotinib for Lung Cancer
Pembrolizumab in Combination With Pemetrexed and Carboplatin Granted FDA Approval as First-Line Treatment in Metastatic Nonsquamous NSCLC
ELCC 2017: Gender Approach to Lung Cancer Screening
Avelumab in Progressive or Treatment-Resistant NSCLC
New Blood Test Identifies Mutations in Patients With Lung Cancer
FDA Grants Lorlatinib Breakthrough Therapy Designation for ALK-Positive Metastatic NSCLC
Brigatinib Receives Accelerated Approval for Locally Advanced or Metastatic ALK-Positive NSCLC
Proton Therapy for Recurrent Lung Cancer
Osimertinib Receives Full FDA Approval for T790M-Positive NSCLC
Quality-of-Life Data From KEYNOTE-024: First-Line Pembrolizumab vs Chemotherapy in Advanced NSCLC
Immunotherapy Combinations Gain Traction in Lung Cancer
Ceritinib Granted Priority Review for ALK-Positive Metastatic NSCLC
Upfront Radiotherapy Tied to Better Outcomes for Brain Metastases in EGFR-Mutant NSCLC
FDA Approves Pembrolizumab as First-Line Treatment for PD-L1–Positive Non–Small Cell Lung Cancer
LUX-Lung 7 Update: Trend for Overall Survival Benefit for Afatinib
Stop EGFR-Targeted TKIs at Progression in NSCLC
New Lung Cancer Staging Manual Set to Modify Clinical Practice
Large Proportion of Patients With NSCLC Not Undergoing EGFR/ALK Biomarker Testing